Ceribell, Inc. is a commercial-stage medical technology company. It is focused on transforming the diagnosis and management of patients with serious neurological conditions. It has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable and rapidly deployable hardware with sophisticated artificial intelligence (AI)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. Point-of-Care EEG enables early detection and management of suspected seizure patients, promoting precise patient care and hospital-wide efficiencies. Its Clarity AI algorithm interprets EEG in real-time, provides bedside alerts and continuous monitoring for status epilepticus. The Ceribell EEG Portal makes it easy to remotely review EEG in real-time with pre-annotated EEG insights.
企業コードCBLL
会社名Ceribell Inc
上場日Oct 11, 2024
最高経営責任者「CEO」Ms. Xingjuan (Jane) Chao, Ph.D.
従業員数281
証券種類Ordinary Share
決算期末Oct 11
本社所在地360 N. Pastoria Avenue
都市SUNNYVALE
証券取引所NASDAQ Global Select Consolidated
国United States of America
郵便番号94085
電話番号18004360826
ウェブサイトhttps://ceribell.com/
企業コードCBLL
上場日Oct 11, 2024
最高経営責任者「CEO」Ms. Xingjuan (Jane) Chao, Ph.D.
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし